SB-505124 hydrochloride hydrate
SIGMA/S4696 - ≥98% (HPLC)
Synonym: 2-
CAS Number: 694433-59-5 (free base)
Empirical Formula (Hill Notation): C20H21N3O2 · xHCl · yH2O
Molecular Weight: 335.40 (anhydrous free base basis)
MDL Number: MFCD11045901
Linear Formula: C20H21N3O2 · xHCl · yH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | yellow |
| form | powder |
| InChI | 1S/C20H21N3O2.ClH.H2O/c1- |
| InChI key | DIDCCMVWCVRTNB-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | O.Cl.Cc1cccc(n1)-c2[nH]c( |
| solubility | DMSO: >10 mg/mL |
| H2O: insoluble | |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Application: | SB-505124 hydrochloride hydrate was used to study the role of TGF-β pathway in development and differentiation studies.3,4 |
| Biochem/physiol Actions: | SB-505124 is an inhibitor of activin receptor-like kinase (ALK) 5, also known as transforming growth factor-α type I receptor kinase, with an IC50 of 47 ± 5 nM. |
| Biochem/physiol Actions: | SB-505124 selectively inhibits TGF-β type I receptors, activin receptor-like kinases (ALK) 4, 5 and 7. It inhibits ALK4-, 5- and 7-mediated activation of Smad2, Smad3 and MAPK pathway induced by TGF-β.1 SB-505124 inhibits the human fibroblast trans-differentiation induced by the co-culture with Esophageal squamous cell carcinoma.2 |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


